| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
Correspondence to: Jack Ansell, Department of Medicine, Boston University Medical Center, 88 E Newton St, Boston, MA 02118; e-mail: jack.ansell{at}bmc.org
This article concerning the pharmacokinetics and pharmacodynamics of vitamin K antagonists (VKAs) is part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. The article describes the antithrombotic effect of VKAs, the monitoring of anticoagulation intensity, the clinical applications of VKA therapy, and the optimal therapeutic range of VKAs, and provides specific management recommendations. Grade 1 recommendations are strong, and indicate that the benefits do, or do not, outweigh the risks, burdens, and costs. Grade 2 suggests that individual patient’s values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S–187S). Among the key recommendations in this article are the following: for dosing of VKAs, we suggest the initiation of oral anticoagulation therapy with doses between 5 and 10 mg for the first 1 or 2 days for most individuals, with subsequent dosing based on the international normalized ratio (INR) response (Grade 2B). In the elderly and in other patient subgroups with an elevated bleeding risk, we suggest a starting dose at 
5 mg (Grade 2C). We recommend basing subsequent doses after the initial two or three doses on the results of INR monitoring (Grade 1C). The article also includes several specific recommendations for the management of patients with INRs above the therapeutic range and for patients requiring invasive procedures. For example, in patients with mild to moderately elevated INRs without major bleeding, we suggest that when vitamin K is to be given it be administered orally rather than subcutaneously (Grade 1A). For the management of patients with a low risk of thromboembolism, we suggest stopping warfarin therapy approximately 4 days before they undergo surgery (Grade 2C). For patients with a high risk of thromboembolism, we suggest stopping warfarin therapy approximately 4 days before surgery, to allow the INR to return to normal, and beginning therapy with full-dose unfractionated heparin or full-dose low-molecular-weight heparin as the INR falls (Grade 2C). In patients undergoing dental procedures, we suggest the use of tranexamic acid mouthwash (Grade 2B) or epsilon amino caproic acid mouthwash without interrupting anticoagulant therapy (Grade 2B) if there is a concern for local bleeding. For most patients who have a lupus inhibitor, we suggest a therapeutic target INR of 2.5 (range, 2.0 to 3.0) [Grade 2B]. In patients with recurrent thromboembolic events with a therapeutic INR or other additional risk factors, we suggest a target INR of 3.0 (range, 2.5 to 3.5) [Grade 2C]. As models of anticoagulation monitoring and management, we recommend that clinicians incorporate patient education, systematic INR testing, tracking, and follow-up, and good communication with patients concerning results and dosing decisions (Grade 1C+).
Key Words: anticoagulation • pharmacology • vitamin K antagonists
This article has been cited by other articles:
|
|
 |
|
  S. G. Johnson, K. Rogers, T. Delate, and D. M. Witt Outcomes Associated With Combined Antiplatelet and Anticoagulant Therapy Chest, April 1, 2008; 133(4): 948 - 954. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hirsh, M. O'Donnell, and J. W. Eikelboom Beyond Unfractionated Heparin and Warfarin: Current and Future Advances Circulation, July 31, 2007; 116(5): 552 - 560. [Full Text] [PDF]
|
|
|
|
|
|
H. Hoppe, J. A. Kaufman, R. E. Barton, B. D. Petersen, P. C. Lakin, T. G. DeLoughery, Z. Irani, K. Yavuz, and F. S. Keller Safety of Inferior Vena Cava Filter Retrieval in Anticoagulated Patients Chest, July 1, 2007; 132(1): 31 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. van Walraven, N. Oake, P. S. Wells, and A. J. Forster Burden of Potentially Avoidable Anticoagulant-Associated Hemorrhagic and Thromobembolic Events in the Elderly Chest, May 1, 2007; 131(5): 1508 - 1515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Delate, D. M. Witt, J. R. Jones, B. Bhardwaja, M. Senser, and for the Clinical Pharmacy Anticoagulation Service Falsely Elevated International Normalized Ratio Values in Patients Undergoing Anticoagulation Therapy: A Descriptive Evaluation Chest, March 1, 2007; 131(3): 816 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Wittkowsky, E. A. Nutescu, J. Blackburn, J. Mullins, J. Hardman, J. Mitchell, and V. Vats Outcomes of Oral Anticoagulant Therapy Managed by Telephone vs In-Office Visits in an Anticoagulation Clinic Setting. Chest, November 1, 2006; 130(5): 1385 - 1389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Lee, E. M. Manno, K. F. Layton, and E. F.M. Wijdicks Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology, October 10, 2006; 67(7): 1272 - 1274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al. ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J. Am. Coll. Cardiol., August 1, 2006; 48(3): e1 - e148. [Full Text] [PDF]
|
|
|
|
|
|
R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al. ACC/AHA 2006 Practice Guidelines for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J. Am. Coll. Cardiol., August 1, 2006; 48(3): 598 - 675. [Full Text] [PDF]
|
|
|
|
 |
|
 L. R Bereznicki, S. L Jackson, and G. M Peterson Comment: Increased Sensitivity to Warfarin after Heart Valve Replacement Ann. Pharmacother., July 1, 2006; 40(7): 1476 - 1477. [Full Text] [PDF]
|
|
|
|
 |
|
 P. de Moerloose, C. M. Samama, and S. Motte Management of venous thromboembolism: [Traitement de la maladie thromboembolique veineuse]. Can J Anesth, June 1, 2006; 53(6_suppl): S80 - S88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Ickx and A. Steib Perioperative management of patients receiving vitamin K antagonists: [Prise en charge perioperatoire des patients traites aux antagonistes de la vitamine K] Can J Anesth, June 1, 2006; 53(6_suppl): S113 - S122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Staresinic, C. A. Sorkness, B. M. Goodman, and D. W. Pigarelli Comparison of outcomes using 2 delivery models of anticoagulation care. Arch Intern Med, May 8, 2006; 166(9): 997 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Lane, C. J. Boos, and G. Y. H. Lip Anticoagulation Control With Vitamin K Antagonists: How Well Are We Doing? Chest, May 1, 2006; 129(5): 1122 - 1124. [Full Text] [PDF]
|
|
|
|
|
|
C. van Walraven, A. Jennings, N. Oake, D. Fergusson, and A. J. Forster Effect of Study Setting on Anticoagulation Control: A Systematic Review and Metaregression Chest, May 1, 2006; 129(5): 1155 - 1166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Marsh and H. L. McLeod Pharmacogenomics: from bedside to clinical practice. Hum. Mol. Genet., April 15, 2006; 15(suppl_1): R89 - R93. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.E. Husted, B.K. Ziegler, and A. Kher Long-term anticoagulant therapy in patients with coronary artery disease Eur. Heart J., April 2, 2006; 27(8): 913 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. DeZee, W. T. Shimeall, K. M. Douglas, N. M. Shumway, and P. G. O'Malley Treatment of Excessive Anticoagulation With Phytonadione (Vitamin K): A Meta-analysis. Arch Intern Med, February 27, 2006; 166(4): 391 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Garcia, S. Regan, M. Crowther, and E. M. Hylek The Risk of Hemorrhage Among Patients With Warfarin-Associated Coagulopathy J. Am. Coll. Cardiol., February 21, 2006; 47(4): 804 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Messmore, J. Fareed, and R. L. Bick Pitfalls in Warfarin Therapy Clinical and Applied Thrombosis/Hemostasis, January 1, 2006; 12(1): 1 - 2. [PDF]
|
|
|
|
 |
|
 C. R. Lee Warfarin Initiation and the Potential Role of Genomic-Guided Dosing Clin. Med. Res., November 1, 2005; 3(4): 205 - 206. [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Gulseth Ximelagatran: An orally active direct thrombin inhibitor Am. J. Health Syst. Pharm., July 15, 2005; 62(14): 1451 - 1467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Eckman "Bridging On the River Kwai": The Perioperative Management of Anticoagulation Therapy Med Decis Making, July 1, 2005; 25(4): 370 - 373. [PDF]
|
|
|
|
 |
|
 M. J. Rieder, A. P. Reiner, B. F. Gage, D. A. Nickerson, C. S. Eby, H. L. McLeod, D. K. Blough, K. E. Thummel, D. L. Veenstra, and A. E. Rettie Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose N. Engl. J. Med., June 2, 2005; 352(22): 2285 - 2293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Singla and G. B. Morrill Warfarin maintenance dosages in the very elderly Am. J. Health Syst. Pharm., May 15, 2005; 62(10): 1062 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Falanga and L. Zacharski Deep vein thrombosis in cancer: the scale of the problem and approaches to management Ann. Onc., May 1, 2005; 16(5): 696 - 701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Stangier, B. I. Eriksson, O. E. Dahl, L. Ahnfelt, G. Nehmiz, H. Stahle, K. Rathgen, and R. Svard Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement J. Clin. Pharmacol., May 1, 2005; 45(5): 555 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S.J. Miller, M. F. Drummond, L. K. Langkilde, J. J.V. McMurray, and M. Ogren Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation Eur. Heart J. Suppl., May 1, 2005; 7(suppl_C): C41 - C54. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Chimowitz, M. J. Lynn, H. Howlett-Smith, B. J. Stern, V. S. Hertzberg, M. R. Frankel, S. R. Levine, S. Chaturvedi, S. E. Kasner, C. G. Benesch, et al. Comparison of Warfarin and Aspirin for Symptomatic Intracranial Arterial Stenosis N. Engl. J. Med., March 31, 2005; 352(13): 1305 - 1316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. J. Koroshetz Warfarin, Aspirin, and Intracranial Vascular Disease N. Engl. J. Med., March 31, 2005; 352(13): 1368 - 1370. [Full Text] [PDF]
|
|
|
|
|
|
A. K. Wittkowsky Factors Associated With INR Elevation and Bleeding Complications During Warfarin Therapy Arch Intern Med, March 28, 2005; 165(6): 703 - 703. [Full Text] [PDF]
|
|
|
|
|
|
C. D Eckhoff, R. J DiDomenico, and N. L Shapiro Initiating Warfarin Therapy: 5 mg versus 10 mg Ann. Pharmacother., December 1, 2004; 38(12): 2115 - 2121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Smythe, W. E. Dager, and N. M. Patel Managing Complications of Anticoagulant Therapy Journal of Pharmacy Practice, October 1, 2004; 17(5): 327 - 346. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
